These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1488 related articles for article (PubMed ID: 26432463)

  • 1. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.
    Leaños-Miranda A; Campos-Galicia I; Berumen-Lechuga MG; Molina-Pérez CJ; García-Paleta Y; Isordia-Salas I; Ramírez-Valenzuela KL
    J Rheumatol; 2015 Jul; 42(7):1141-9. PubMed ID: 25979720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.
    Erez O; Romero R; Espinoza J; Fu W; Todem D; Kusanovic JP; Gotsch F; Edwin S; Nien JK; Chaiworapongsa T; Mittal P; Mazaki-Tovi S; Than NG; Gomez R; Hassan SS
    J Matern Fetal Neonatal Med; 2008 May; 21(5):279-87. PubMed ID: 18446652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of angiogenic biomarkers and uterine artery Doppler in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome.
    Rodríguez-Almaraz ME; Herraiz I; Gómez-Arriaga PI; Vallejo P; Gonzalo-Gil E; Usategui A; López-Jiménez EA; Galindo A; Galindo M
    Pregnancy Hypertens; 2018 Jan; 11():99-104. PubMed ID: 29523283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
    Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study.
    Myers JE; Kenny LC; McCowan LM; Chan EH; Dekker GA; Poston L; Simpson NA; North RA;
    BJOG; 2013 Sep; 120(10):1215-23. PubMed ID: 23906160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy.
    Crovetto F; Figueras F; Triunfo S; Crispi F; Rodriguez-Sureda V; Peguero A; Dominguez C; Gratacos E
    Fetal Diagn Ther; 2014; 35(4):258-66. PubMed ID: 24714555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes.
    Coolman M; Timmermans S; de Groot CJ; Russcher H; Lindemans J; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VV; Steegers EA
    Obstet Gynecol; 2012 Jun; 119(6):1190-200. PubMed ID: 22617584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.
    Chaiworapongsa T; Romero R; Savasan ZA; Kusanovic JP; Ogge G; Soto E; Dong Z; Tarca A; Gaurav B; Hassan SS
    J Matern Fetal Neonatal Med; 2011 Oct; 24(10):1187-207. PubMed ID: 21827221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.
    Kleinrouweler CE; Wiegerinck MM; Ris-Stalpers C; Bossuyt PM; van der Post JA; von Dadelszen P; Mol BW; Pajkrt E;
    BJOG; 2012 Jun; 119(7):778-87. PubMed ID: 22433027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
    PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
    Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
    J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.